{
    "address": "Gammahuset, Ideongatan 1",
    "city": "Lund",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W1674V299",
    "description": "BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 74 full-time employees. The company went IPO on 2001-06-12. The Company\u2019s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.",
    "employeeTotal": "74.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2001-06-12",
    "isin": "SE0015244520",
    "logo": "https://finnhub.io/api/logo?symbol=BINV.ST",
    "marketCapitalization": 2982.026,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "BioInvent International AB",
    "phone": "46462868550.0",
    "sedol": "BKY6BX3",
    "shareOutstanding": 58.471,
    "state": "SKANE",
    "ticker": "BINV.ST",
    "weburl": "http://www.bioinvent.se/"
}